Expected Estradiol and Progesterone Levels on Day 2 of Menstrual Cycle Before HRT
On day 2 of the menstrual cycle, estradiol (E2) should be low at approximately 16-20 pg/mL (44-55 pmol/L), and progesterone (P4) should be at baseline levels below 1-2 ng/mL (3-6 nmol/L), as both hormones remain suppressed during the early follicular phase before ovulation occurs.
Physiological Context
Estradiol Levels
- During the early follicular phase (days 1-3), estradiol remains at baseline levels, typically ranging from 16.6 to 20.5 pg/mL in women with regular menstrual cycles 1.
- These low E2 levels reflect minimal follicular activity before the mid-cycle surge 1.
- Estradiol begins rising only after day 3-5 as follicles develop, reaching peak levels of 150-200 pg/mL per mature follicle during the pre-ovulation period 2.
Progesterone Levels
- Progesterone remains at low baseline throughout the follicular phase from menstruation onset until ovulation, which typically occurs between days 9-20 3.
- Baseline progesterone during menstruation is typically below 2 ng/mL (6 nmol/L) 3.
- Progesterone only rises significantly after ovulation during the luteal phase, reaching peak concentrations in the mid-luteal period 3.
- Mid-luteal progesterone values below 6 nmol/L indicate anovulation 3.
Clinical Implications for HRT Initiation
Diagnostic Confirmation Before HRT
- When evaluating for premature ovarian insufficiency (POI) before starting HRT, FSH and estradiol should be measured together 2.
- A low estradiol level (<50 pg/mL) combined with elevated FSH (>25 IU/L) confirms hypoestrogenism and supports the diagnosis of POI 2.
- The assay should be repeated 1 month later if initial results show low estradiol and high FSH 2.
- Measuring hormones on day 2-3 of the cycle avoids confounding from the pre-ovulation peak or estradiol-secreting cysts 2.
Baseline Assessment
- Day 2 measurements establish true baseline values before initiating replacement therapy 2.
- These baseline values help distinguish between physiological early follicular phase levels and pathological hypoestrogenism requiring HRT 2.
Important Caveats
Factors That Invalidate Measurements
- Women using combined estrogen-progestin contraception or macro-progestins will have falsely suppressed FSH levels, requiring withdrawal of antigonadotropic treatment for at least 3 months before repeat testing 2.
- Pregnancy must be ruled out before interpreting hormone levels 2.
Monitoring After HRT Initiation
- FSH levels cannot be used to monitor HRT adequacy because estrogen is not the only regulator of FSH secretion; inhibin also plays a role 4.
- Serum FSH may remain elevated despite adequate estrogen replacement of target tissues 4.
- Routine hormone level monitoring is not required for assessing HRT adequacy; clinical symptom control is the primary endpoint 5.
- If symptoms persist despite escalating doses, particularly after changing from oral to transdermal administration, estradiol levels may be measured to guide dose adjustment 6.
Target Levels on HRT
- Physiological E2 levels can generally be reached with 100 µg transdermal 17β-estradiol patch or 2 mg oral estradiol, achieving concentrations appropriate for women in their early 40s 2, 5.
- Women with POI may require higher estrogen doses than women with physiological menopause to achieve adequate symptom control 2.